business / news / / The Financial Express
Eli Lilly’s market share in the GLP-1 category of drugs dropped from 61% in March to 56% in February.
Eli Lilly’s tirzepatide brand Mounjaro sales dropped 21% in March after semaglutide generics launched.
KEY POINTS
- Novo Nordisk slashed Wegovy prices by 36% in April to match Indian generic competitors.
- Semaglutide’s market share in India’s GLP-1 segment rose from 25% in February to 33% in March.
- Twelve Indian companies launched 23 generic semaglutide brands within three weeks of patent expiry.
- Semaglutide’s patent remains valid in the US and Europe until the early 2030s.
COMPANIES
Summarized by Newsio from The Financial Express. How we summarize →